How Rescheduling Delay Will Impact Trulieve Stock Investors

Simply Wall St.

Oct 01

DEA Chief Judge Derek Julius paused the federal cannabis rescheduling case earlier this week, halting progress on a potential shift of marijuana under the Controlled Substances Act that many Trulieve ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/news/2672763669"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2672763669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2672763669?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","is_english":true,"pubTime":"2026-10-01 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2672763669","market":"nz","top_or_hot":-1,"title":"How Rescheduling Delay Will Impact Trulieve Stock Investors","media":"Simply Wall St.","content":"<div>\n<p>DEA Chief Judge Derek Julius paused the federal cannabis rescheduling case earlier this week, halting progress on a potential shift of marijuana under the Controlled Substances Act that many Trulieve ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/how-rescheduling-delay-will-impact-trulieve-stock-investors\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Rescheduling Delay Will Impact Trulieve Stock Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Rescheduling Delay Will Impact Trulieve Stock Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-01 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/how-rescheduling-delay-will-impact-trulieve-stock-investors><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DEA Chief Judge Derek Julius paused the federal cannabis rescheduling case earlier this week, halting progress on a potential shift of marijuana under the Controlled Substances Act that many Trulieve ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/how-rescheduling-delay-will-impact-trulieve-stock-investors\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/how-rescheduling-delay-will-impact-trulieve-stock-investors","article_id":"2672763669","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/how-rescheduling-delay-will-impact-trulieve-stock-investors","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2672763669","pubTimestamp":1790864450,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"DEA Chief Judge Derek Julius paused the federal cannabis rescheduling case earlier this week, halting progress on a potential shift of marijuana under the Controlled Substances Act that many Trulieve Cannabis investors had been watching closely.\nThe stay highlights how much Trulieve Cannabis’s tax burden, capital planning and long term store and production strategy still hinge on unpredictable federal timing rather than only on consumer demand.\nWe will now look at how this rescheduling delay...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","MSOX":"AdvisorShares MSOX 2X Daily ETF","CNBS":"Amplify Seymour Cannabis ETF","YOLO":"AdvisorShares Pure Cannabis ETF","TRLV":"Trulieve Cannabis Corporation","TOKE":"Cambria Cannabis ETF","BK4007":"制药","MJ":"Amplify Alternative Harvest ETF","MSOS":"AdvisorShares Pure US Cannabis ETF","BK4211":"区域性银行","WEED":"Roundhill Cannabis ETF"},"translate_title":"重新安排延迟将如何影响 Trulieve 股票投资者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNBS":0.9,"MSOS":0.9,"TOKE":0.9,"ISBC":1.5,"YOLO":0.9,"WEED":0.9,"TRLV":1,"MJ":0.9,"MSOX":0.9},"content_text":"DEA Chief Judge Derek Julius paused the federal cannabis rescheduling case earlier this week, halting progress on a potential shift of marijuana under the Controlled Substances Act that many Trulieve Cannabis investors had been watching closely. The stay highlights how much Trulieve Cannabis’s tax burden, capital planning and long term store and production strategy still hinge on unpredictable federal timing rather than only on consumer demand. We will now look at how this rescheduling delay could reshape Trulieve Cannabis’s investment narrative that was built around regulatory relief.  Scan beyond Trulieve Cannabis and see how other cannabis and consumer-facing operators stack up on balance sheet strength and fundamentals with our curated list of solid balance sheet and fundamentals (25 results). AdvertisementTrulieve Cannabis Investment Narrative Recap To own Trulieve Cannabis, investors need to be comfortable with a medically focused operator that is still unprofitable but runs a large, multi state platform and leans heavily on future regulatory relief. The DEA stay does not change day to day execution. It does, however, delay clarity on 280E relief that many viewed as the clearest short term potential boost to cash flow and margins. The biggest near term risk remains execution amid ongoing pricing pressure and softer consumer wallets, while Trulieve Cannabis continues to spend on new capacity, store upgrades and technology projects such as Project Hyper. If demand or pricing do not ultimately justify this build out, returns on that spending and the quality of earnings could come under pressure. With no new company announcements directly tied to the DEA pause, the most relevant reference point remains management’s earlier framing of federal rescheduling and Schedule III as an important lever for tax relief and cash generation. The stay simply lengthens the timeline for when investors might see any potential tax savings reflected in Trulieve Cannabis’s reported margins and free cash flow. That shifts more attention back to internal levers. The company reported US$353 million of cash against US$290 million of debt and positive free cash flow of US$42 million in the quarter. Execution on Project Hyper, the mobile app and rewards ecosystem, and the wholesale ramp to US$22 million of quarterly revenue all take on greater importance while the regulatory catalyst is on hold. Trulieve Cannabis' current analyst narrative points to forecast revenues of US$933.9 million and projected earnings of US$183.7 million by 2029, based on an assumed 6.4% yearly decline in revenue and an earnings swing of about US$651.5 million from a loss of US$467.8 million today. Uncover how Trulieve Cannabis' fair value indicates a 67% potential upside to its current price before the discount to Trulieve Cannabis closes. NYSE:TRLV 1-Year Stock Price Chart Exploring Other Perspectives One alternate Trulieve Cannabis storyline leans hard into the DEA rescheduling as a catalyst. The most optimistic analysts were projecting about US$893.0 million of revenue and earnings of US$433.3 million by 2029 before this pause. You can treat that as a best case that might be rethought as rules and timing evolve. Explore 3 other Trulieve Cannabis fair value estimates, including one that suggests there could be as much as 73% upside from the current price! The Verdict Is Yours Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Trulieve Cannabis research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Trulieve Cannabis. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Trulieve Cannabis' overall financial health at a glance.  Looking for more investment ideas beyond Trulieve Cannabis? Trulieve Cannabis is only one way to express a view on regulation, cash generation and balance sheet strength. If you want to widen the opportunity set and compare it with other businesses on clear, fundamentals driven filters, the Simply Wall St Screener can help surface stocks that better fit your risk and return goals.  If capital preservation is a priority, start with resilient businesses that screen well on financial strength and lower risk using our 31 resilient stocks with low risk scores. For investors focused on quality at a sensible entry point, filter for stronger fundamentals and pricing that looks more reasonable through the 31 high quality undervalued stocks. If you prefer companies that are less picked over by the market, cast a wider net with our 19 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Trulieve Cannabis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}